Does GLP-1-RA use affect the incidence of OA diagnosis and conversion to arthroplasty in patients with or without preexisting OA?
GLP-1-RAs may have direct disease-modifying effects in osteoarthritis independent of weight loss, though their effects may differ based on preexisting disease status.
GLP-1-RAs may provide direct disease-modifying behaviors in patients with preexisting OA diagnosis, per a reduced risk of conversion to TJA not attributable to weight loss. Further investigation is also needed to elucidate the association between GLP-1-RA use and the increased incidence of OA diagnosis and conversion to TKA in patients with no preexisting OA diagnosis.
Porto et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: